GlassScriptPhysician profile
Marc A Warmuth
NPI 1265429989
$1,013.20
in general payments reported to CMS, 2019-2025
29 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.99 · 2020: $44.44 · 2021: $69.25 · 2022: $75.78 · 2023: $191 · 2024: $221 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.74 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $168.56 | 2023-2025 | |
| Tempus Ai, INC | $94.96 | 2025 | Xt Cdx |
| Janssen Biotech, INC. | $83.22 | 2022-2025 | Rybrevant, Talvey, Darzalex |
| Alexion Pharmaceuticals, INC. | $78.63 | 2021-2024 | Ultomiris |
| Pfizer INC. | $63.70 | 2021-2025 | |
| Daiichi Sankyo INC. | $55.97 | 2019-2025 | Enhertu |
| Alnylam Pharmaceuticals INC. | $40.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $40.14 | 2023-2024 | Lynparza, Enhertu |
| Genentech USA, INC. | $39.70 | 2023-2024 | Polivy |
| Incyte Corporation | $34.26 | 2023-2024 | Monjuvi, Pemazyre, Jakafi |
| Coherus Oncology, INC. | $30.06 | 2023 | |
| Merck Sharp & Dohme LLC | $29.68 | 2019-2024 | Keytruda |
| Fennec Pharmaceuticals, INC. | $25.46 | 2025 | Fyarro |
| Secura Bio, INC. | $18.39 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $18.20 | 2025 | Sancuso |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $17.58 | 2025 | Optune Lua (Novottf-200t) |
| Genzyme Corporation | $16.76 | 2024 | |
| Taiho Oncology, INC. | $15.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.37 | 2024 | Fruzaqla |
| Agios Pharmaceuticals, INC. | $14.66 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $14.20 | 2024 | Onivyde, Somatuline Depot |
| Abbvie INC. | $13.92 | 2025 | |
| Eisai INC. | $13.60 | 2020 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.76 | 2019 | |
| Lilly USA, LLC | $11.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.23 | 2019 | |
| Aurobindo Pharma USA, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Warmuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.